WO2001032159A3 - Methods and formulations for the treatment of infectious bursal disease in avian subjects - Google Patents

Methods and formulations for the treatment of infectious bursal disease in avian subjects Download PDF

Info

Publication number
WO2001032159A3
WO2001032159A3 PCT/US2000/030066 US0030066W WO0132159A3 WO 2001032159 A3 WO2001032159 A3 WO 2001032159A3 US 0030066 W US0030066 W US 0030066W WO 0132159 A3 WO0132159 A3 WO 0132159A3
Authority
WO
WIPO (PCT)
Prior art keywords
infectious bursal
subject
treatment
formulas
ibd
Prior art date
Application number
PCT/US2000/030066
Other languages
French (fr)
Other versions
WO2001032159A2 (en
Inventor
Christine C Dykstra
James C Hudson
Richard R Tidwell
David Boykin
Sandra Ewald
Original Assignee
Univ North Carolina
Univ Auburn
Georgia State University Res
Christine C Dykstra
James C Hudson
Richard R Tidwell
David Boykin
Sandra Ewald
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ North Carolina, Univ Auburn, Georgia State University Res, Christine C Dykstra, James C Hudson, Richard R Tidwell, David Boykin, Sandra Ewald filed Critical Univ North Carolina
Priority to AU14504/01A priority Critical patent/AU1450401A/en
Publication of WO2001032159A2 publication Critical patent/WO2001032159A2/en
Publication of WO2001032159A3 publication Critical patent/WO2001032159A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Abstract

In one aspect, the invention relates to a method of treating infectious bursal disease (IBD) in an avian subject in need of such treatment. The method comprises administering to the subject a compound of the formulas (I) through (IV) or a pharmaceutically acceptable salt thereof in an amount sufficient to treat IBD. In another aspect, the invention relates to a method of producing active immunity against infectious bursal virus disease (IBD) in an avian subject. The method comprises administering to a subject an immunogenic-amount of an IBDV vaccine and a compound selected from the compounds of formulas (I) through (IV) described herein. The compound represented by formulas (I) through (IV) is administered in an amount sufficient to induce an immune response in the avian subject.
PCT/US2000/030066 1999-11-01 2000-11-01 Methods and formulations for the treatment of infectious bursal disease in avian subjects WO2001032159A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU14504/01A AU1450401A (en) 1999-11-01 2000-11-01 Methods and formulations for the treatment of infectious bursal disease in avian subjects

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16287799P 1999-11-01 1999-11-01
US60/162,877 1999-11-01

Publications (2)

Publication Number Publication Date
WO2001032159A2 WO2001032159A2 (en) 2001-05-10
WO2001032159A3 true WO2001032159A3 (en) 2002-07-11

Family

ID=22587500

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/030066 WO2001032159A2 (en) 1999-11-01 2000-11-01 Methods and formulations for the treatment of infectious bursal disease in avian subjects

Country Status (2)

Country Link
AU (1) AU1450401A (en)
WO (1) WO2001032159A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7163955B2 (en) 2001-01-13 2007-01-16 The University Of North Carolina At Chapel Hill Compounds, methods and compositions useful for the treatment of bovine viral diarrhea virus (BVDV) infection and hepatitis C virus (HCV) infection
US7262223B2 (en) 2004-01-23 2007-08-28 Neurochem (International) Limited Amidine derivatives for treating amyloidosis
EP2120952A4 (en) * 2007-01-15 2011-09-21 Us Of America As Represented By The Secretary Of The Army On Behalf Of The U S Army Res Inst Of Infe Antiviral compounds and methods of using thereof
MX2010004361A (en) * 2007-10-24 2010-09-10 Functional Genetics Inc Methods of inhibiting viral infection.

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4324794A (en) * 1980-08-26 1982-04-13 Research Triangle Institute Inhibition of respiratory syncytial virus-induced cell fusion by amidino compounds
US5308838A (en) * 1982-05-07 1994-05-03 Carrington Laboratories, Inc. Uses of aloe products
WO1995019772A1 (en) * 1994-01-20 1995-07-27 The University Of North Carolina At Chapel Hill Use of bis(amidinobenzimidazoles) in the manufacture of medicament for inhibiting retroviral integrase
US5521189A (en) * 1994-05-06 1996-05-28 The University Of Nc At Ch Methods of treating pneumocystis carinii pneumonia
WO1996040117A1 (en) * 1995-06-07 1996-12-19 The University Of North Carolina At Chapel Hill Methods of treating microbial infections
US5668166A (en) * 1995-06-07 1997-09-16 Georgia State University Research Foundation, Inc. Methods of inhibiting pneumocystis carinii pneumonia and compounds useful therefor
EP0941991A1 (en) * 1998-02-27 1999-09-15 University Of North Carolina At Chapel Hill 2,4-Bis (4-amidino)phenyl furans as anti-pneumocystis carinii agents

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4324794A (en) * 1980-08-26 1982-04-13 Research Triangle Institute Inhibition of respiratory syncytial virus-induced cell fusion by amidino compounds
US5308838A (en) * 1982-05-07 1994-05-03 Carrington Laboratories, Inc. Uses of aloe products
WO1995019772A1 (en) * 1994-01-20 1995-07-27 The University Of North Carolina At Chapel Hill Use of bis(amidinobenzimidazoles) in the manufacture of medicament for inhibiting retroviral integrase
US5521189A (en) * 1994-05-06 1996-05-28 The University Of Nc At Ch Methods of treating pneumocystis carinii pneumonia
WO1996040117A1 (en) * 1995-06-07 1996-12-19 The University Of North Carolina At Chapel Hill Methods of treating microbial infections
US5668166A (en) * 1995-06-07 1997-09-16 Georgia State University Research Foundation, Inc. Methods of inhibiting pneumocystis carinii pneumonia and compounds useful therefor
EP0941991A1 (en) * 1998-02-27 1999-09-15 University Of North Carolina At Chapel Hill 2,4-Bis (4-amidino)phenyl furans as anti-pneumocystis carinii agents

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
"dictionary of the english language", INTERNET, XP002175541 *
BERGHOT, MOGED AHMED ET AL: "Facile synthesis of novel carbazoles through heterocyclization reactions and their antimicrobial activity", REV. ROUM. CHIM. (1995), 40(4), 377-86, XP001034863 *
BOYKIN D ET AL: "Anti-Pneumocystis carinii pneumonia activity of dicationic diaryl methylpyrimidines", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, EDITIONS SCIENTIFIQUE ELSEVIER, PARIS, FR, vol. 32, no. 12, 1 December 1998 (1998-12-01), pages 965 - 972, XP004108373, ISSN: 0223-5234 *
DUBOVI E.J. ET AL: "Inhibition of respiratory syncytial virus by bis(5-amidino-2- benzimidazolyl)methane.", VIROLOGY, (1980) 103/2 (502-504). CODEN: VIRLAX, XP001020491 *
FRANCESCONI, IRIS ET AL: "2,4-Diphenyl furan diamidines as novel anti-Pneumocystis carinii pneumoni agents", J. MED. CHEM. (1999), 42(12), 2260-2265, XP001034838 *
HILDEBRANDT, ELLEN ET AL: "Identification and characterization of an endo/exonuclease in Pneumocysti carinii that is inhibited by dicationic diarylfurans with efficacy agains Pneumocystis pneumonia", J. EUKARYOTIC MICROBIOL. (1998), 45(1), 112-121, XP000924813 *
KUMAR A ET AL: "Anti-Pneumocystis carinii pneumonia activity of dicationic 2,4-diarylpyrimidines", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, EDITIONS SCIENTIFIQUE ELSEVIER, PARIS, FR, vol. 31, no. 10, 1996, pages 767 - 773, XP004070190, ISSN: 0223-5234 *
TIDWELL, RICHARD R. ET AL: "Suppression of respiratory syncytial virus infection in cotton rats by bis(5-amidino-2-benzimidazolyl)methane", ANTIMICROB. AGENTS CHEMOTHER. (1984), 26(4), 591-3, XP001020488 *
XIAO, G. ET AL: "Inhibition of the HIV-1 Rev-RRE complex formation by unfused aromatic cations", BIOORG. MED. CHEM. (2001), 9(5), 1097-1113, XP002185880 *

Also Published As

Publication number Publication date
AU1450401A (en) 2001-05-14
WO2001032159A2 (en) 2001-05-10

Similar Documents

Publication Publication Date Title
WO2001090121A3 (en) Methods and compositions for treating hepatitis c virus
JP2003506416A5 (en)
CA2410488A1 (en) Methods of treating hepatitis delta virus infection with .beta.-l-2' deoxy-nucleosides
HK1045941A1 (en) Treatment of allergies
WO2005049074A3 (en) Methods for modulating the th2 immuneresponse to an antigen by adding or removing activated carbonyl groups from the antigen
WO2002000266A3 (en) A method of treating and preventing infectious diseases
JP2003513935A5 (en)
WO2001032159A3 (en) Methods and formulations for the treatment of infectious bursal disease in avian subjects
JP2003522768A5 (en)
RU97104483A (en) SUITABLE ACID SALT 4- [2-AMINO-6- (CYCLOPROPYLAMINO) -9H-PURIN-9-IL] -2- CYCLOPENTEN-1-METHANOL AS ANTI-VIRUS AGENT
FR2725990B1 (en) WATER-SOLUBLE DERIVATIVES OF EPIPODOPHYLLOTOXIN, PROCESS FOR THEIR PREPARATION, THEIR USE AS MEDICAMENTS, AND THEIR USE FOR CANCER TREATMENTS
CA2457804A1 (en) Transcutaneous immunization against papillomavirus with papillomavirus virus-like particles
WO2002017917A8 (en) Manzamines for treatment of drug resistant infection
WO2005084157A3 (en) Methods of treating disease through the administration of a manzamine analog or derivative
WO2001022994A3 (en) Vaccines against neisseria infection
RU98101105A (en) NEW APPLICATION FOR MEDICAL PURPOSES
WO2005013920A3 (en) Newcastle disease virus administration
EP0351908A1 (en) Live newcastle disease virus vacccines
US6383741B2 (en) Method for treatment of canine distemper
WO2004013298A3 (en) 2',3'-dideoxynucleoside analogues for the treatment or prevention of flavivitridae infections
WO2004100640A3 (en) Marek’s disease virus vaccine
WO2002020051A3 (en) Equine infectious anemia challenge model for testing vaccines, diagnostics and treatments
WO2001054718A3 (en) Compositions and method for preventing reactogenicity associated with administration of immunogenic live rotavirus compositions
WO2001039760A3 (en) Method of treating batten disease
WO2001028541A2 (en) Composition comprising sildenafil and l-arginine

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase